EPHA5抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human fetal brain tissue, mouse kidney tissue, Primary antibody: P08091(CALB1 Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 40 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08091(CALB1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The EphA5 antibody is a tool used to detect and study the EphA5 receptor, a member of the Eph receptor tyrosine kinase family. Eph receptors, the largest subgroup of receptor tyrosine kinases (RTKs), are critical mediators of cell-cell communication, particularly in developmental processes and disease contexts. EphA5 specifically binds ephrin-A ligands, triggering bidirectional signaling pathways that regulate cell adhesion, migration, and tissue patterning. It is prominently expressed in the nervous system, where it influences axon guidance, synaptic plasticity, and neuronal survival. Dysregulation of EphA5 has been implicated in neurological disorders (e.g., Alzheimer’s disease) and cancers (e.g., gliomas, prostate cancer), where it may drive tumor progression or metastasis.

EphA5 antibodies are essential for research applications like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to map EphA5 expression and localization in tissues or cell lines. These antibodies typically target specific epitopes within EphA5’s extracellular ligand-binding domain or intracellular kinase domain. Commercially available antibodies vary in clonality (monoclonal/polyclonal), species reactivity (human, mouse, rat), and validation standards. Recent studies also explore EphA5’s role as a therapeutic target, with antibodies being tested for diagnostic or inhibitory potential. However, challenges remain in ensuring antibody specificity and reproducibility across experimental models, necessitating rigorous validation controls.